Regional Cerebral Blood Flow Patterns and Response to Donepezil Treatment in Patients with Alzheimer’s Disease

We attempted to identify the characteristic patterns in regional cerebral blood flow (rCBF) of patients with Alzheimer’s disease who responded to donepezil therapy. Sixty-one patients treated with donepezil were divided into two groups (responders and nonresponders) on the basis of changes in their Mini Mental State Examination (MMSE) scores from baseline to study endpoint. We analyzed single-photon emission computed tomography data (SPECT) at baseline using three-dimensional stereotactic surface projections and compared differences in rCBF between the two groups. Statistical maps showed a significantly lower rCBF of the lateral and medial frontal lobes in the nonresponders than in the responders. There was a significant inverse correlation between the relative rCBF reduction in the frontal lobe and the MMSE change. These results suggest that frontal function, as assessed by SPECT, affects the patient’s response to treatment with donepezil. Measuring rCBF may aid in the selection of possible treatment responders.

[1]  C. Vidal.  Nicotinic potentiation of glutamatergic synapses in the prefrontal cortex: New insight into the analysis of the role of nicotinic receptors in cognitive functions , 1994 .

[2]  E. Giacobini,et al.  Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease. , 2000, Alzheimer disease and associated disorders.

[3]  R. Koeppe,et al.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  R T Staff,et al.  Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy , 2000, Nuclear medicine communications.

[5]  A. Kurz,et al.  Reduction of regional cerebral blood flow and cognitive impairment in patients with Alzheimer's disease: evaluation of an observer-independent analytic approach. , 1997, Dementia and geriatric cognitive disorders.

[6]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[7]  D. Neary,et al.  Single photon emission tomography using 99mTc-HM-PAO in the investigation of dementia. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[8]  A W Toga,et al.  Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[9]  D. Jenden,et al.  Cholinesterase Inhibition Improves Blood Flow in the Ischemic Cerebral Cortex , 1997, Brain Research Bulletin.

[10]  J. Muir,et al.  Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron , 1995, Psychopharmacology.

[11]  J. Talairach,et al.  Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .

[12]  B. Sahakian,et al.  Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB , 2005, Psychopharmacology.

[13]  E. Mohr,et al.  Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[14]  R. Koeppe,et al.  Anatomic standardization: linear scaling and nonlinear warping of functional brain images. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  B. Everitt,et al.  AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[16]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[17]  L. Sands,et al.  Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors. , 1999, Alzheimer disease and associated disorders.

[18]  G. Goodwin,et al.  Cerebral Pharmacodynamics of Physostigmine in Alzheimer's Disease Investigated Using Single-Photon Computerised Tomography , 1991, British Journal of Psychiatry.

[19]  M. Mega,et al.  The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. , 1999, Archives of neurology.

[20]  ML Voytko,et al.  Basal forebrain lesions in monkeys disrupt attention but not learning and memory [published erratum appears in J Neurosci 1995 Mar;15(3): following table of contents] , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[21]  H. Hanyu,et al.  Diagnostic accuracy of single photon emission computed tomography in Alzheimer's disease. , 1993, Gerontology.

[22]  N. Lassen,et al.  Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: a [99mTc]-d,l-HMPAO SPECT study. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[23]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[24]  B L Holman,et al.  The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  J. Rusted,et al.  Cholinergic control of cognitive resources. , 1993, Neuropsychobiology.

[26]  S Minoshima,et al.  Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.